August 8, 2022
Oncolys BioPharma President Yasuo Urata Tokyo-based biotech Oncolys BioPharma is sticking to its 2024 target for the regulatory submission of its oncolytic virus telomelysin in Japan even after Chugai Pharmaceutical walked away from their collaboration deal, according to President Yasuo...read more